Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Avalyn Pharma Inc.

AVLN · Nasdaq · CIK 0001540171 · Healthcare · Biotechnology

INSIDER SIGNAL

69.5 / 100

3 buyers · 4 purchase transaction lines · $25.0M gross purchase

WHY THIS SIGNAL?

Buyer breadthModerate
Purchase sizeStrong
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+21.0 / 35
Purchase size+23.9 / 25
Role+14.0 / 20
Recency+0.6 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: TenPercentOwner (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS3
PURCHASE CONCENTRATION40%Largest buyer: Novo Holdings A/S · $10.0M
CLUSTER BUYING · 15D3 insidersPeak activity: 2026-05-01–2026-05-01

Roles in the peak window: Director, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Novo Holdings A/STenPercentOwner
○●
Carroll JillDirector
○●
George Simeon; SR ONE CAPITAL MANAGEMENT, LLCTenPercentOwner
○●
FMR LLCTenPercentOwner,Other
○
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.TenPercentOwner
○
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

69.5 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 69.6
  2. 69.6
  3. 69.5
  4. 69.5
  5. 69.5

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

4Purchases
0Sales
12Other Form 4 lines
5SEC filings · 365 days
BUYING4 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER12 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-25.7%
3M
-7.5%
6M
—
12M
—

Volatility & liquidity

Volatility
64.0%
Beta
—
Avg daily value
USD 6.3M

Valuation

Market cap
USD 1.1B
P/E
—

Fundamentals

Profit margin
—
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
2,516,254
Previous report
2,093,252
Avg daily volume
295,206
Days to cover
8.5

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-01Novo Holdings A/SPurchase (P)Voting Common Stock555,555USD 18.00USD 9,999,990SEC filing ↗
2026-05-01George Simeon; SR ONE CAPITAL MANAGEMENT, LLCPurchase (P)Common Stock555,555USD 18.00USD 9,999,990SEC filing ↗
2026-05-01Carroll JillPurchase (P)Common Stock277,778USD 18.00USD 5,000,004SEC filing ↗

Form 4 evidence

16 transaction lines in the latest 365-day window; 16 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-01Novo Holdings A/SPurchase (P)Voting Common Stock555,555USD 18.00USD 9,999,990SEC filing ↗
2026-05-01Novo Holdings A/SC (C)Voting Common Stock3,327,734USD —USD —SEC filing ↗
2026-05-01FMR LLCC (C)Common Stock2,284,535USD —USD —SEC filing ↗
Show recent Form 4 evidence (8 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-01Novo Holdings A/SPurchase (P)Voting Common Stock555,555USD 18.00USD 9,999,990SEC filing ↗
2026-05-01Novo Holdings A/SC (C)Voting Common Stock3,327,734USD —USD —SEC filing ↗
2026-05-01FMR LLCC (C)Common Stock2,284,535USD —USD —SEC filing ↗
2026-05-01Wellington Biomedical Innovation Master Investors (Cayman) II L.P.C (C)Common Stock1,275,486USD —USD —SEC filing ↗
2026-05-01George Simeon; SR ONE CAPITAL MANAGEMENT, LLCPurchase (P)Common Stock555,555USD 18.00USD 9,999,990SEC filing ↗
2026-05-01George Simeon; SR ONE CAPITAL MANAGEMENT, LLCC (C)Common Stock2,263,608USD —USD —SEC filing ↗
2026-05-01Carroll JillPurchase (P)Common Stock277,778USD 18.00USD 5,000,004SEC filing ↗
2026-05-01Carroll JillC (C)Common Stock1,908,784USD —USD —SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerAVLN
CIK0001540171
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history16 transaction lines from 2026-05-01 to 2026-05-01
4 P purchase lines · 0 S sale lines · 12 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.